Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 8/20 | 0.57 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238787 | 0.79 | CYSLTR1 (0.62) | CYSLTR1CYSLTR2CYP1A2GPBAR1PDE10A | |
| SCHEMBL30824506 | 0.79 | CYSLTR1 (0.62) | CYSLTR1CYSLTR2CYP1A2GPBAR1PDE10A | |
| SCHEMBL2353460 | 0.79 | CYSLTR1 (0.67) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL9844656 | 0.77 | CYSLTR1 (0.55) | CYSLTR1CYSLTR2CYP1A2GPBAR1PDE10A | |
| SCHEMBL30718634 | 0.77 | BACE1 (0.45) | CYSLTR1CYSLTR2CYP1A2GPBAR1PDE10A | |
| SCHEMBL7504609 | 0.77 | CYSLTR1 (0.55) | CYSLTR1CYSLTR2CYP1A2GPBAR1PDE10A | |
| SCHEMBL8557157 | 0.77 | CYP1A2 (0.51) | CYSLTR1CYSLTR2CYP1A2GPBAR1PDE10A | |
| SCHEMBL14508065 | 0.77 | KCNH2 (0.47) | CYSLTR1GPBAR1 | |
| SCHEMBL4268808 | 0.76 | CYSLTR1 (0.59) | CYSLTR1CYSLTR2CYP1A2GPBAR1PDE10A | |
| SCHEMBL13118218 | 0.76 | CYP1A2 (0.54) | CYSLTR1CYSLTR2CYP1A2GPBAR1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105814040-B | The condensed 1,4- dihydro two of inhibitor as thermal excited transcryption factor 1 dislikes ene derivative | 癌症研究科技有限公司 | 2019-07-30 | — | — | CN | disclosed |
| US-20180215727-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215727-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20110160196-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160196-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20080293704-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293704-A1 | FACTOR Xa INHIBITORS | TFPI, F12, F11 | CYSLTR1 2655/4885CYSLTR2 2948/4885CYP1A2 234/4885 |
| US-20110160196-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | CYSLTR1 2655/4885CYSLTR2 2948/4885CYP1A2 234/4885 |
| US-20180215727-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | CYSLTR1 93/4885CYSLTR2 44/4885CYP1A2 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.